US Stock MarketDetailed Quotes
VRNA Verona Pharma
- 21.670
- +2.140+10.96%
Trading Aug 8 15:18 ET
1.76BMarket Cap-13543P/E (TTM)
21.756High19.790Low727.97KVolume20.090Open19.530Pre Close15.09MTurnover16.29%Turnover RatioLossP/E (Static)81.24MShares23.72052wk High10.46P/B96.84MFloat Cap11.39052wk Low--Dividend TTM4.47MShs Float26.440Historical High--Div YieldTTM10.07%Amplitude2.010Historical Low20.733Avg Price1Lot Size
Verona Pharma Stock Forum
Sign in to post a comment
$Verona Pharma (VRNA.US)$ earnings on 8/8 and hopefully new announcements!
1
1
$Verona Pharma (VRNA.US)$ and finally it seems all brakes are loose and it is going to the top!
1
$Verona Pharma (VRNA.US)$ Price pressure has begun in pre-market, which looks unreal for a company receicing approval for a novel - and potentially groundbreaking - drug.
Stay calm, dont play in the hands of the shorts. Make sure your stock cannot be borrowed for shorts as well.
Stay calm, dont play in the hands of the shorts. Make sure your stock cannot be borrowed for shorts as well.
4
1
$Verona Pharma (VRNA.US)$ shorters will try to push it down. this is a long term hold being a blockbuster drug, with a 2 billion potential further down the road. revenue forecast for this year 40 million. hopefully conference call is giving the price a boost. if a big pharma might do a take over, it goes sky rocketing. whatever it is, don’t sell cheap. Disclaimer: not financial advice.
5
$Verona Pharma (VRNA.US)$ Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine) 2 HOURS AGO, 4:57 PM EDT VIA GLOBENEWSWIRE: Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH,...
🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co (MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma (VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab (GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co (MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
📌 This week’s PDUFAs:
$Merck & Co (MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma (VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab (GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co (MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
9
$Sarepta Therapeutics (SRPT.US)$ : ELEVIDYS
$Harmony Biosciences (HRMY.US)$ : WAKIX (pitolisant)
$Bristol-Myers Squibb (BMY.US)$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE (ARGX.US)$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co (MRK.US)$ : Patritumab deruxtecan
$Verona Pharma (VRNA.US)$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals (RCKT.US)$ : KRESLADI (Marnetegragene autotemcel)
$Harmony Biosciences (HRMY.US)$ : WAKIX (pitolisant)
$Bristol-Myers Squibb (BMY.US)$ : KRAZATI (Adagrasib) + Cetuximab
$argenx SE (ARGX.US)$ : VYVGART Hytrulo (Efgartigimod)
$Merck & Co (MRK.US)$ : Patritumab deruxtecan
$Verona Pharma (VRNA.US)$ : Ensifentrine (Nebulized)
$Rocket Pharmaceuticals (RCKT.US)$ : KRESLADI (Marnetegragene autotemcel)
14
The company is 7 days away from a very likely FDA approval which will give them a shot in the arm, dissolving their debt in less than a year when going to market.
This article does not even mention the upcoming approval date and is a sign of incomplete journalism.
This article does not even mention the upcoming approval date and is a sign of incomplete journalism.
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Boxman : Conference call 9AM !